108 related articles for article (PubMed ID: 22524132)
1. [HE4--a new tumor marker for ovarian cancer].
Manolov V; Marinov B; Vasilev V; Andreeva A
Akush Ginekol (Sofiia); 2011; 50 Suppl 2():11-5. PubMed ID: 22524132
[TBL] [Abstract][Full Text] [Related]
2. [HE4 and CA125 in ovarian cancer].
Manolov V; Marinov B; Vasilev V
Akush Ginekol (Sofiia); 2012; 51(2):21-8. PubMed ID: 23234010
[TBL] [Abstract][Full Text] [Related]
3. [The values of serum human epididymis secretory protein 4 and CA(125) assay in the diagnosis of ovarian malignancy].
Dong L; Chang XH; Ye X; Zhu LR; Zhao Y; Tian L; Cheng HY; Li XP; Zhang H; Liao QP; Fu TY; Cheng YX; Cui H
Zhonghua Fu Chan Ke Za Zhi; 2008 Dec; 43(12):931-6. PubMed ID: 19134334
[TBL] [Abstract][Full Text] [Related]
4. [Diagnostic value of combining detection of human epididymis protein 4 and CA125 in patients with malignant ovarian carcinoma].
Wang MJ; Qi J; Wang H; Li XX; Wei BJ; Fu C; Gao J; Han BB
Zhonghua Zhong Liu Za Zhi; 2011 Jul; 33(7):540-3. PubMed ID: 22093635
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic performances of HE4 and CA125 for the detection of ovarian cancer from patients with various gynecologic and non-gynecologic diseases.
Park Y; Lee JH; Hong DJ; Lee EY; Kim HS
Clin Biochem; 2011 Jul; 44(10-11):884-8. PubMed ID: 21549107
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of HE4 as an extrabiomarker to CA125 to improve detection of ovarian carcinoma: is it time for a step forward?
Azzam AZ; Hashad DI; Kamel NA
Arch Gynecol Obstet; 2013 Jul; 288(1):167-72. PubMed ID: 23361457
[TBL] [Abstract][Full Text] [Related]
7. Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer.
Baron AT; Boardman CH; Lafky JM; Rademaker A; Liu D; Fishman DA; Podratz KC; Maihle NJ
Cancer Epidemiol Biomarkers Prev; 2005 Feb; 14(2):306-18. PubMed ID: 15734951
[TBL] [Abstract][Full Text] [Related]
8. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass.
Moore RG; Brown AK; Miller MC; Skates S; Allard WJ; Verch T; Steinhoff M; Messerlian G; DiSilvestro P; Granai CO; Bast RC
Gynecol Oncol; 2008 Feb; 108(2):402-8. PubMed ID: 18061248
[TBL] [Abstract][Full Text] [Related]
9. [Ovarian tumor markers of presumed benign ovarian tumors].
Lahlou N; Brun JL
J Gynecol Obstet Biol Reprod (Paris); 2013 Dec; 42(8):752-9. PubMed ID: 24210243
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence.
Havrilesky LJ; Whitehead CM; Rubatt JM; Cheek RL; Groelke J; He Q; Malinowski DP; Fischer TJ; Berchuck A
Gynecol Oncol; 2008 Sep; 110(3):374-82. PubMed ID: 18584856
[TBL] [Abstract][Full Text] [Related]
11. Serum concentrations of HE4 change little during in vitro fertilization.
Hallamaa M; Huhtinen K; Suvitie P; Perheentupa A
Acta Obstet Gynecol Scand; 2014 Jul; 93(7):640-6. PubMed ID: 24734893
[TBL] [Abstract][Full Text] [Related]
12. Afamin and apolipoprotein A-IV: novel protein markers for ovarian cancer.
Dieplinger H; Ankerst DP; Burges A; Lenhard M; Lingenhel A; Fineder L; Buchner H; Stieber P
Cancer Epidemiol Biomarkers Prev; 2009 Apr; 18(4):1127-33. PubMed ID: 19336561
[TBL] [Abstract][Full Text] [Related]
13. Combined detection of sialic acid and hydroxyproline in diagnosis of ovarian cancer and its comparison with human epididymis protein 4 and carbohydrate antigen 125.
Li PL; Zhang X; Li TF; Wang LL; Du LT; Yang YM; Li J; Wang HY; Zhang Y; Wang CX
Clin Chim Acta; 2015 Jan; 439():148-53. PubMed ID: 25445414
[TBL] [Abstract][Full Text] [Related]
14. [Measurement of serum human epididymis secretory protein 4 combined with CA125 assay in differential diagnosis of endometriosis cyst and ovarian benign and malignant tumors].
Liu YN; Ye X; Cheng HY; Cheng YX; Fu TY; Chen J; Chang XH; Cui H
Zhonghua Fu Chan Ke Za Zhi; 2010 May; 45(5):363-6. PubMed ID: 20646446
[TBL] [Abstract][Full Text] [Related]
15. Statistical interpretation of CA125 and Bcl-2 in serum of patients with late stage ovarian cancer.
Camlica H; Duranyildiz D; Tas F; Yasasever V
Am J Clin Oncol; 2008 Dec; 31(6):585-8. PubMed ID: 19060592
[TBL] [Abstract][Full Text] [Related]
16. HE4 in ovarian cancer: from discovery to clinical application.
Montagnana M; Danese E; Giudici S; Franchi M; Guidi GC; Plebani M; Lippi G
Adv Clin Chem; 2011; 55():1-20. PubMed ID: 22126021
[TBL] [Abstract][Full Text] [Related]
17. [Serum tumor markers CA125 and HE4 in ovarian cancer patients].
Sergeeva NS; Marshutina NV; Alentov II; Korneeva IA; Novikova EG
Vopr Onkol; 2013; 59(2):12-21. PubMed ID: 23814844
[No Abstract] [Full Text] [Related]
18. Two-marker combinations for preoperative discrimination of benign and malignant ovarian masses.
Freydanck MK; Laubender RP; Rack B; Schuhmacher L; Jeschke U; Scholz C
Anticancer Res; 2012 May; 32(5):2003-8. PubMed ID: 22593479
[TBL] [Abstract][Full Text] [Related]
19. [Clinical value of serum CA19-9, CA125 and CP2 in mucinous ovarian tumor: a retrospective study of 273 patients].
Dong L; Cui H; Li XP; Sun LF; Chang XH; Liang XD; Zhu HL
Zhonghua Fu Chan Ke Za Zhi; 2008 Jan; 43(1):5-8. PubMed ID: 18366923
[TBL] [Abstract][Full Text] [Related]
20. [HE4, a novel marker for epithelial ovarian cancer: evaluation of analytical performances].
Lamy PJ; Roques S; Viglianti C; Fabbro M; Montels F
Ann Biol Clin (Paris); 2010; 68(3):325-9. PubMed ID: 20478777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
